|
Market Closed -
Nasdaq
00:00:00 02/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 8.940 USD | -5.60% |
|
+4.32% | -69.02% |
| 09-14 | Capricor Therapeutics Shares Rise After Upgrade From B. Riley | MT |
| 09-14 | B. Riley Upgrades Capricor Therapeutics to Buy From Neutral, Raises Price Target to $21 From $5 | MT |
Company Valuation: Capricor Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 70.76 | 97.43 | 150.6 | 627.5 | 1,493 | 519.8 | - | - |
| Change | - | 37.7% | 54.55% | 316.72% | 137.87% | -65.18% | - | - |
| Enterprise Value (EV) | 70.76 | 97.43 | 150.6 | 476 | 1,493 | 519.8 | 519.8 | 519.8 |
| Change | - | 37.7% | 54.55% | 216.1% | 213.59% | -65.18% | 0% | 0% |
| P/E | -3.37x | -3.27x | -5.89x | -12x | -12.8x | -4.87x | -6x | 55.2x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0.1x | 0.2x | -0.3x | -0.1x | 0.3x | 0.3x | -0x |
| Capitalization / Revenue | 289x | 38.2x | 5.98x | 28.2x | - | 9.33x | 9.19x | 3.6x |
| EV / Revenue | 0x | 0x | 0x | 0x | - | 9.33x | 9.19x | 3.6x |
| EV / EBITDA | -0x | -0x | -0x | -0x | -0x | -4.19x | -2.8x | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -4.24x | -6.18x | -25.6x |
| EV / FCF | - | - | - | -0x | -0x | -6.34x | -6.98x | -10.3x |
| FCF Yield | - | - | - | -6.62% | -4.9% | -15.8% | -14.3% | -9.72% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.87 | -1.18 | -0.83 | -1.15 | -2.26 | -1.834 | -1.49 | 0.162 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 0.2449 | 2.551 | 25.18 | 22.27 | - | 55.69 | 56.54 | 144.5 |
| EBITDA 1 | -20.94 | -29.16 | -22.79 | -41.14 | -106.3 | -124 | -185.9 | - |
| EBIT 1 | -20.94 | -29.7 | -23.86 | -42.56 | -108.1 | -122.5 | -84.08 | -20.27 |
| Net income 1 | -20.02 | -29.02 | -22.29 | -40.47 | -105 | -132 | -89.51 | 7.711 |
| Net Debt | - | - | - | -151.5 | - | - | - | - |
| Reference price 2 | 2.930 | 3.860 | 4.890 | 13.800 | 28.860 | 8.940 | 8.940 | 8.940 |
| Nbr of stocks (in thousands) | 24,149 | 25,241 | 30,793 | 45,470 | 51,718 | 58,139 | - | - |
| Announcement Date | 10/03/22 | 15/03/23 | 29/02/24 | 19/03/25 | 12/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.87x | - | - | - | 520M | |
| 21.73x | 7.77x | 15.61x | 1.37% | 74.41B | |
| 30.79x | 8.87x | 27.62x | 0.04% | 59.26B | |
| 32.79x | 5.89x | 17.64x | 0.99% | 47.14B | |
| 33.58x | 3.26x | 14.07x | -.--% | 42.91B | |
| -21.23x | 229.92x | -22.88x | -.--% | 44.13B | |
| 46.86x | 5.42x | 29.73x | -.--% | 40.79B | |
| 27.79x | 7.97x | 20.59x | 0.41% | 30.77B | |
| 33.94x | 7.26x | 18.84x | -.--% | 29.31B | |
| -66.62x | 12.77x | -65.09x | -.--% | 23.71B | |
| Average | 13.48x | 32.13x | 6.24x | 0.31% | 39.3B | |
| Weighted average by Cap. | 19.52x | 32.23x | 10.39x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- CAPR Stock
- Valuation Capricor Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
